{"owner": "ArrayExpress Uploader", "pop_total": 0, "species": "mouse", "factors": [{"GSM1298154": {"GENOTYPE": "bitransgenic Pdx1-cre/Kras*A", "CELL TYPE": "pancreatic tumor"}}, {"GSM1298154": {"GENOTYPE": "bitransgenic Pdx1-cre/Kras*A", "CELL TYPE": "pancreatic tumor"}}, {"GSM1298154": {"GENOTYPE": "bitransgenic Pdx1-cre/Kras*A", "CELL TYPE": "pancreatic tumor"}}, {"GSM1298154": {"GENOTYPE": "bitransgenic Pdx1-cre/Kras*A", "CELL TYPE": "pancreatic tumor"}}, {"GSM1298154": {"GENOTYPE": "bitransgenic Pdx1-cre/Kras*A", "CELL TYPE": "pancreatic tumor"}}, {"GSM1298154": {"GENOTYPE": "bitransgenic Pdx1-cre/Kras*A", "CELL TYPE": "pancreatic tumor"}}, {"GSM1298160": {"GENOTYPE": "WT", "CELL TYPE": "pancreatic cells"}}, {"GSM1298160": {"GENOTYPE": "WT", "CELL TYPE": "pancreatic cells"}}, {"GSM1298160": {"GENOTYPE": "WT", "CELL TYPE": "pancreatic cells"}}, {"GSM1298160": {"GENOTYPE": "WT", "CELL TYPE": "pancreatic cells"}}, {"GSM1298160": {"GENOTYPE": "WT", "CELL TYPE": "pancreatic cells"}}], "id": 7532, "ownerprofile_id": "arrayexpress_sid", "platform": 6, "summary_wrapped": "We have carried out transcriptional profile analysis in WT MICE and bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal...", "geo_gse_id": "E-GEOD-53659", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 2, "sample_count": 11, "tags": ["adenocarcinoma", "cancer", "ductal adenocarcinoma", "pancreatic ductal adenocarcinoma"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "expression-data-from-wt-mice-and-bitransgenic-pdx1", "geo_id_plat": "E-GEOD-53659_A-AFFY-45", "name": "Expression data from WT mice and bitransgenic Pdx1-cre/Kras*A mice bearing Pancreatic Ductal Adenocarcinoma", "created": "Nov.12, 2014", "summary": "We have carried out transcriptional profile analysis in WT MICE and bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal Adenocarcinoma Mouse models faithfully simulating human cancer are valuable for genetic identification of potential  drug-targets but, among them, the most advantageous for practical use in subsequent preclinical  testing of candidate therapeutic regimes are those exhibiting rapid tumor development. Considering  that a KRAS mutation (predominantly in codon 12, such as KRASG12D; KRAS*) occurs with high  frequency (~90%) in cases of human pancreatic ductal adenocarcinoma (PDA)1, we sought to develop  a mouse PDA model that would exhibit high tumor incidence and short latency by ectopic  overexpression of Kras*. Five WT mice and 6  bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal Adenocarcinoma were used to identify key genes in the formation of panceatic malignacies", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-53659", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-53659/samples/"}